DALLAS, Oct. 27, 2009 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Generex Biotechnologies Corp. (Nasdaq:GNBT). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Generex Biotechnologies Corp. (Nasdaq:GNBT) should be of particular interest to other biotechnology companies: CPEX Pharmaceuticals Inc. (Nasdaq:CPEX), MannKind Corp. (Nasdaq:MNKD), Novo Nordisk (NYSE:NVO) and Hospira Inc. (NYSE:HSP).
It is available at: http://www.investorsoup.com/lp/GNBT
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup
Generex Biotechnology Corporation (GNBT) is engaged in the research, development and commercialization of drug delivery systems and technologies. The Company focuses on its technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator.
Message Board Search for GNBT: http://www.boardcentral.com/boards/GNBT
In the report, the analyst notes:
"GNBT last week also announced that its consolidated financial statements for the fiscal year ended July 31, 2009, contained a going concern qualification from its independent registered public accounting firm. Nasdaq Marketplace Rule 5250(b)(2) requires separate public disclosure of a previously issued audit opinion that contains a going concern qualification. This announcement does not represent any change or amendment to the Company's financial statements for the fiscal year ended July 31, 2009.
"GNBT last week announced it has received its first purchase order for Generex Oral-lyn(TM) from Continental Pharm Laboratories, a pharmaceutical products distributor in Algeria. The order consists of 10,000 canisters of Generex Oral-lyn(TM), which will be filled by the Company's Middle Eastern branch office, Generex MENA (Middle East and Northern Africa), located in Dubai Healthcare City. Generex MENA is responsible for more than 20 countries and has relationships with more than 31 distributors for each of the various product lines and territories who have already begun commercializing the Company's confectionary product lines, and out of those countries, eight are actively pursuing regulatory approval for Generex Oral-lyn(TM), the Company's proprietary oral insulin spray product, and have filed the Generex Oral-lyn(TM) dossier with their respective regulatory authorities."
To read the entire report visit: http://www.investorsoup.com/lp/GNBT
See what investors say about these stocks at: http://www.stockhideout.com/
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.